Q3 2021 13F Holders as of 30 Sep 2021
-
Type / Class
-
Equity / Common Stock, $0.001 par value
-
Shares outstanding
-
1.64M
-
Number of holders
-
33
-
Total 13F shares, excl. options
-
6.67M
-
Shares change
-
-313K
-
Total reported value, excl. options
-
$60.8M
-
Value change
-
-$2.65M
-
Number of buys
-
9
-
Number of sells
-
-23
-
Price
-
$9.13
Significant Holders of Lyra Therapeutics, Inc. - Common Stock, $0.001 par value (LYRA) as of Q3 2021
41 filings reported holding LYRA - Lyra Therapeutics, Inc. - Common Stock, $0.001 par value as of Q3 2021.
Lyra Therapeutics, Inc. - Common Stock, $0.001 par value (LYRA) has 33 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 6.67M shares
.
Largest 10 shareholders include PERCEPTIVE ADVISORS LLC (3.22M shares), Polaris Venture Management Co. V, L.L.C. (1.1M shares), PURA VIDA INVESTMENTS, LLC (533K shares), Ikarian Capital, LLC (403K shares), VANGUARD GROUP INC (220K shares), Soleus Capital Management, L.P. (216K shares), ArrowMark Colorado Holdings LLC (139K shares), Parian Global Management LP (121K shares), MILLENNIUM MANAGEMENT LLC (118K shares), and BANK OF AMERICA CORP /DE/ (111K shares).
This table shows the top 33 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.